Database

Startups

Main Industry
Biotechnology
Main Product/Service
EDEN BIOSIMILAR
Founded Year
2012
Unified Business No.
54151980
Status
Active
Number of Employees
0
Total Paid-in Capital
3,059,391,410 (NT$)
Location of Company
Taiwan , New Taipei City
Exit Status
Emerging Stock Exchange(2015)、Acquired(2022)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
About the Company
Founded in 2012, Eden Biologics is an innovator in biopharmaceuticals that utilizes breakthrough engineering and process technologies to provide high quality and affordable biosimilar medicines to patients in need and a formidable CDMO player for global and regional clients. Eden has submitted IND/CTA’s to over 20+ countries/regions and has passed numerous Regulatory Audits/Inspections, including from the Taiwan FDA and EU Qualified Person (QP).
EDEN’s vision is to improve global healthcare by increasing the availability of biotechnology medicines and making them affordable for ALL in need. The individual color blocks in our logo represents the pioneering aspects of our company: innovative technologies, state-of-the-art equipment, professional leadership and experienced workforce. The resulting “E” gels these together. If you zoom out, the logo includes green hills, golden fields and a dazzling sun as we envision building a better, healthier world through EDEN.



more ↓

Similar Companies

AMARAN BIOTECHNOLOGY, INC.

1. Adjuvants
2. Drug Substance Manufacturing
3. Drug Product Manufacturing
4. Stability Study & Analytical Science Services
5. Sourcing & Consultation Services

EIRGENIX, INC.

1. Trastuzumab Biosimilar
2. CDMO Services
3. CRM197 Carrier Protein
4. COVID-19 Antigen Rapid Test

ANYA BIOPHARM INC.

ORAL PEPTIDE
Summary of development timelines-product
MIRA/JE® Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal st
:::
回頁面最頂端